A multisite surveillance study published in Pediatrics assessed trends and determinants of influenza antiviral use in hospitalized children across the United States before and during the late COVID-19...
Researchers compared high-dose versus standard-dose influenza vaccines in adults aged 65 to 79 years to determine whether enhanced immunogenicity translates into reduced severe clinical outcomes, including...
A new phase 3 trial evaluated whether a quadrivalent modified mRNA influenza vaccine could match or exceed the efficacy of a licensed inactivated influenza vaccine in adults aged 18–64 years during the...
New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
From respiratory syncytial virus monoclonal antibody approvals to thimerosal-free vaccine preferences, ACIP’s latest guidance has important implications for your practice.
A randomized trial comparing influenza vaccines over two seasons found that recombinant vaccines showed stronger immune responses to A/H3N2 strains compared with egg-based and cell culture-based vaccines.
...
